切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2018, Vol. 06 ›› Issue (04) : 216 -221. doi: 10.3877/cma.j.issn.2095-5820.2018.04.006

所属专题: 文献

.实验研究.

儿童急性B淋巴细胞白血病患者诱导化疗后免疫表型的改变及其临床意义
代庆凯1, 彭欢1, 陈岚1, 陈琪1, 江咏梅1,()   
  1. 1. 610041 成都,四川大学华西第二医院检验科,出生缺陷与相关妇儿疾病教育部重点实验室
  • 收稿日期:2018-08-09 出版日期:2018-11-28
  • 通信作者: 江咏梅

Changes of immunophenotype in children with acute B lymphoblastic leukemia after induction chemotherapy and its clinical significance

Qingkai Dai1, Huan Peng1, Lan Chen1, Qi Chen1, Yongmei Jiang1,()   

  1. 1. Department of laboratory medicine, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China
  • Received:2018-08-09 Published:2018-11-28
  • Corresponding author: Yongmei Jiang
  • About author:
    Corresponding author: Jiang Yongmei, Email:
引用本文:

代庆凯, 彭欢, 陈岚, 陈琪, 江咏梅. 儿童急性B淋巴细胞白血病患者诱导化疗后免疫表型的改变及其临床意义[J/OL]. 中华临床实验室管理电子杂志, 2018, 06(04): 216-221.

Qingkai Dai, Huan Peng, Lan Chen, Qi Chen, Yongmei Jiang. Changes of immunophenotype in children with acute B lymphoblastic leukemia after induction chemotherapy and its clinical significance[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2018, 06(04): 216-221.

目的

探讨儿童急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)诱导结束时白血病细胞抗原表达的变化情况及其对预后的影响。

方法

回顾性研究于2010年至2015年期间被诊断为B-ALL的691例儿童患者。患儿骨髓标本在初诊时进行白血病免疫分型检测,并在治疗第33天时进行微小残留病(minimal residual disease,MRD)检测。其中,155例MRD≥0.01%的患者被纳入本次研究。用四色单克隆荧光抗体组合通过多参数流式细胞术进行白血病细胞免疫表型变化的研究。

结果

86例(55.5%)患者至少有一个抗原标志出现了表型转换,CD19是最稳定的标记。然而,将近1/3患儿的CD20在初诊和化疗第33天时表达有显著性差异。抗原表达的变化与无事件生存率(event-free survival,EFS)、无复发生存率(relapse-free survival,RFS)或总生存率(overall survival,OS)无显着相关(P>0.05)。多因素分析显示白细胞计数(white blood cell,WBC)和BCR-ABL在儿童ALL中具有独立的预后价值。

结论

虽然抗原表达的改变在诱导缓解治疗结束时很普遍,但是在化疗第33天MRD阳性的患者中,抗原表达的改变与预后价值无关。

Objective

To investigate the changes in antigen expressions on leukemic cells and its effect on prognosis at the end of induction in children with acute lymphoblastic leukemia (ALL).

Methods

The retrospective study included 691 children diagnosed with B-ALL between 2010 and 2015. The bone marrow specimens of the children were used for the detection of leukemia immunophenotype at the first diagnosis, and for the detection of minimal residual disease (MRD) at the 33rd day of treatment. Among them, 155 patients with MRD greater than 0.01% were included in this study. The immunophenotypic changes of leukemia cells were studied by using a four-color monoclonal fluorescent antibody combination through multi-parameter flow cytometry.

Results

86 of 155 (55.5%) cases showed phenotype shifts at least one marker. CD19 was the most stable markers. However, nearly one third of the children had significant differences in CD20 expression on the 33rd day of initial diagnosis and chemotherapy. Changes in antigen expression were not significantly correlated with event-free survival (EFS), relapse-free survival (RFS) or overall survival (OS) (P>0.05). Multivariate analysis showed that white blood cell (WBC) and BCR-ABL had independent prognostic value in ALL.

Conclusion

Although changes in antigen expression were common at the end of induction remission therapy, they were not associated with prognostic value in patients with MRD positive on day 33 of chemotherapy.

表1 155例B-ALL患儿的临床生物学特征
表2 免疫表型的改变和预后价值的单因素分析
表3 17例患者诱导缓解化疗后和复发时抗原表达的变化(例)
图1 Kaplan-Meier生存曲线
[1]
Hunger SP,Mullighan CG. Acute lymphoblastic leukemia in children[J]. N Engl J Med, 2015,373(16):1541-1552.
[2]
Brüggemann M,Raff T,Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia[J]. Blood, 2006,107(3):1116-1123.
[3]
Pui CH,Campana D,Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation[J]. N Engl J Med, 2009,360(26):2730-2741.
[4]
Faderl S,O′Brien S,Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies[J]. Cancer, 2010,116(5):1165-1176.
[5]
Campana D,Neale GA,Coustan-Smith E, et al. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience[J]. Leukemia, 2001,15(2):278–279.
[6]
Weir EG,Cowan K,LeBeau P, et al. A limited antibody panel can dis-tinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection[J]. Leukemia, 1999,13(4):558-567.
[7]
Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia[J]. Curr Opin Hematol, 2012,19(4):313-318.
[8]
Pui CH,Pei D,Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a pro-spective study[J]. Lancet Oncol, 2015,16(4):465-474.
[9]
Conter V,Bartram CR,Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study[J]. Blood, 2010,115(16):3206-3214.
[10]
Coustan-Smith E,Sancho J,Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Blood, 2000,96(8):2691-2696.
[11]
Coustan-Smith E,Ribeiro RC,Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leu-kemia who have a superior clinical outcome[J]. Blood, 2006,108(1):97-102.
[12]
Schrappe M,Valsecchi MG,Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study[J]. Blood, 2011,118(8):2077-2084.
[13]
Gaipa G,Basso G,Biondi A, et al. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2013,84(6):359-369.
[14]
Tomová A,Babusiková O. Shifts in expression of immunological cell markers in relapsed acute leukemia[J]. Neoplasma, 2001,48(3):164-168.
[15]
Hur M,Chang YH,Lee DS, et al. Immunophenotypic and cyto-genetic changes in acute leukaemia at relapse[J]. Clin Lab Haematol, 2001,23(3):173-179.
[16]
Coustan-Smith E,Behm FG,Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia[J]. Lancet, 1998,351(9102):550-554.
[17]
Baer MR,Stewart CC,Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)[J]. Blood, 2001,97(11):3574-3580.
[18]
Abshire TC,Buchanan GR,Jackson JF, et al. Morphologic, immunologic and cytogenetic studies in children with acute lym-phoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study[J]. Leukemia, 1992,6(5):357-362.
[19]
Guglielmi C,Cordone I,Boecklin F, et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications[J]. Leukemia, 1997,11(9):1501-1507.
[20]
Bennet JM,Catovsky D,Daniel MT, et al. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlation[J]. Br J Haematol, 1981,47(4):553-561.
[21]
Lucio P,Gaipa G,van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric im-munophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: in-ternational standardization and clinical evaluation[J]. Leukemia, 2001,15(8):1185-1192.
[22]
Wang Y,Peng L,Dai Q, et al. Clinical value to quantitate hematogones in Chinese childhood acute lymphoblastic leukemia by flow cytometry analysis[J]. Int J Lab Hematol, 2016,38(3):246-255.
[23]
Bayram I,Erbey F,Kömür M, et al. Flow cytometry results at diagnosis and relapse in childhood acute lymphoblastic leukemia[J]. Asian Pac J Cancer Prev, 2010,11(5):1321-1324.
[24]
Campana D,Coustan-Smith E,Janossy G. The immunologic detection of minimal residual disease in acute leukemia[J]. Blood, 1990,76(1):163-171.
[25]
Borowitz MJ,Pullen DJ,Winick N, et al. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children′s oncology group[J]. Cytometry B Clin Cytom, 2005,68(1):18-24.
[26]
Van Wering ER,Beishuizen A,Roeffen ET, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia[J]. Leukemia, 1995,9(9):1523-1533.
[27]
Burnusuzov HA,Spasova MI,Murdjeca MA, et al. Immunophenotypic modulation of the blast cells in childhood acute lymphoblastic leukemia minimal residual disease detection[J]. Folia Med, 2016,58(1): 28-35.
[28]
Gaipa G,Basso G,Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal re-sidual disease detection[J]. Leukemia, 2005,19(1):49-56.
[29]
Dworzak MN,Schumich A,Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leu-kemia during induction treatment: setting the stage for anti-CD20 directed im-munotherapy[J]. Blood, 2008,112(10):3982-3988.
[30]
Slamova L,Starkova J,Fronkova E, et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage[J]. Leukemi, 2013,28(2014):609-620.
[31]
Vidriales MB,Pérez JJ,López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value[J]. Blood, 2003,101(12):4695-4700.
[32]
Gökbuget N,Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults[J]. Rev Clin Exp Hematol, 2002,6(2):114-141.
[33]
Thomas X,Danaïla C,Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period[J]. Leukemia, 2001,37(12):1811-1822.
[34]
Verma A,Stock W. Management of adult acute lymphoblastic leukemia: moving toward a riskadapted approach[J]. Curr Opin Oncol, 2001,13(1):14-20.
[35]
Schultz KR,Pullen DJ,Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lympho-blastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children′s Cancer Group (CCG)[J]. Blood, 2007,109(3):926-935.
[36]
Aricò M,Valsecchi MG,Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000,342(14):998-1006.
[37]
Pieters R. Infant acute lymphoblastic leukemia: lessons learned and future direc-tions[J]. Curr Hematol Malig Rep, 2009,4(3):167-174.
[38]
Gao C,Zhao XX,Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1004 patients[J]. Am J Hematol, 2012,87(11):1022-1027.
[39]
Teachey DT,Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia[J]. Br J Haematol, 2013,162(5):606-620.
[40]
Aricò M,Schrappe M,Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-po-sitive acute lymphoblastic leukemia treated between 1995 and 2005[J]. J Clin Oncol, 2010,28(31):4755-4761.
[1] 陶宏宇, 叶菁菁, 俞劲, 杨秀珍, 钱晶晶, 徐彬, 徐玮泽, 舒强. 右心声学造影在儿童右向左分流相关疾病中的评估价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 959-965.
[2] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[3] 向韵, 卢游, 杨凡. 全氟及多氟烷基化合物暴露与儿童肥胖症相关性研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 569-574.
[4] 王雅楠, 刘丹, 曹正浓, 贾慧敏. 儿童迟发性先天性膈疝患儿的临床诊治特点分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 410-419.
[5] 陈桂华, 钟小玲, 谢雨, 王慧, 谢江, 杨涛毅. 合并肝脏疾病特殊健康状态儿童疫苗预防接种及时性临床分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 431-439.
[6] 雷丽莉, 于晓峰, 王媛媛, 徐迎军. 人鼻病毒感染喘息急性发作儿童外周血NLRP3和TLR4水平及临床意义[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 440-445.
[7] 刘静, 王燕妮, 王继萍. 儿童毛发移植应用前景及病例讨论[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(04): 368-368.
[8] 郑宝英, 黄小兰, 贾楠, 朱春梅. 儿童难治性肺炎支原体肺炎早期预警指标[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 215-221.
[9] 刘冉佳, 崔向丽, 周效竹, 曲伟, 朱志军. 儿童肝移植受者健康相关生存质量评价的荟萃分析[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 302-309.
[10] 丁荷蓓, 王珣, 陈为国. 七氟烷吸入麻醉与异丙酚静脉麻醉在儿童腹股沟斜疝手术中的应用比较[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 570-574.
[11] 中华医学会器官移植学分会, 中华医学会外科学分会外科手术学学组, 中华医学会外科学分会移植学组, 华南劈离式肝移植联盟. 劈离式供肝儿童肝移植中国临床操作指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 593-601.
[12] 刘军, 丘文静, 孙方昊, 李松盈, 易述红, 傅斌生, 杨扬, 罗慧. 在体与离体劈离式肝移植在儿童肝移植中的应用比较[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 688-693.
[13] 张琛, 秦鸣, 董娟, 陈玉龙. 超声检查对儿童肠扭转缺血性改变的诊断价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 565-568.
[14] 陈晓胜, 何佳, 刘方, 吴蕊, 杨海涛, 樊晓寒. 直立倾斜试验诱发31 秒心脏停搏的植入心脏起搏器儿童一例并文献复习[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 488-494.
[15] 曹亚丽, 高雨萌, 张英谦, 李博, 杜军保, 金红芳. 儿童坐位不耐受的临床进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 510-515.
阅读次数
全文


摘要